Trials / Recruiting
RecruitingNCT03838926
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trichostatin A | Intravenous Infusion |
Timeline
- Start date
- 2018-09-27
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2019-02-12
- Last updated
- 2026-03-16
Locations
11 sites across 2 countries: United States, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03838926. Inclusion in this directory is not an endorsement.